Basonuclin 2 Activators
Basonuclin 2 activators function through mechanisms that primarily modulate intracellular cyclic AMP (cAMP) levels, which in turn regulate the activity of protein kinase A (PKA), a key kinase known to engage in the phosphorylation of target proteins, thereby altering their function and activity. The activation of adenylate cyclase by certain small molecules causes an upsurge in cAMP synthesis, while other molecules achieve similar results by inhibiting phosphodiesterases, enzymes that degrade cAMP. The resultant elevated cAMP levels lead to an enhancement of PKA activity; this kinase is pivotal as it may directly phosphorylate Basonuclin 2, leading to changes in its DNA-binding affinity and nuclear localization, thus increasing its functional activity.
Other activators influence the cAMP pathway indirectly by modulating related enzymes, such as nitric oxide synthase, which can affect the guanylate cyclase pathway and subsequently cAMP levels. The manipulation of cAMP levels, whether by inhibition of its degradation or increased synthesis, orchestrates the activation of PKA. Once active, PKA may target Basonuclin 2, enabling it to execute its biological roles more effectively. The indirect interventions in the cGMP pathway also play a role in maintaining cAMP levels, as some molecules also modulate the balance between cAMP and cGMP by influencing the activity of phosphodiesterases, which degrade these cyclic nucleotides.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-specific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP. Elevated cAMP levels can lead to activation of PKA, which can subsequently phosphorylate and activate Basonuclin 2. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a phosphodiesterase inhibitor that increases intracellular cAMP levels, potentially enhancing PKA activity and leading to the phosphorylation and activation of Basonuclin 2. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a selective inhibitor of phosphodiesterase 4, increases cAMP levels in cells, promoting PKA activation. Activated PKA can phosphorylate Basonuclin 2, resulting in its activation. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
L-NAME is an inhibitor of nitric oxide synthase. The reduction of nitric oxide levels can influence the guanylate cyclase pathway, indirectly affecting cAMP levels and therefore the activity of PKA, which may activate Basonuclin 2. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a phosphodiesterase (PDE1) inhibitor that increases cAMP levels, which can lead to PKA-mediated activation of Basonuclin 2. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Inhibits phosphodiesterase 3, leading to increased cAMP levels and PKA activation. This activation cascade can lead to phosphorylation and subsequent activation of Basonuclin 2. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is another phosphodiesterase 3 inhibitor, which raises intracellular cAMP levels and promotes PKA activity, potentially leading to the phosphorylation and activation of Basonuclin 2. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits phosphodiesterase activity and increases cAMP levels, which may promote activation of PKA and subsequent activation of Basonuclin 2. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
A beta2-adrenergic agonist that stimulates adenylate cyclase, increasing cAMP levels and activating PKA, which in turn may activate Basonuclin 2. | ||||||